Glucagen Kit

Glucagen Kit is a prescription‑only injectable solution that contains the peptide hormone glucagon. It is supplied in a ready‑to‑use kit for intramuscular, intravenous, or subcutaneous administration. The product is marketed in the European Union and is classified as an antihypoglycemic agent (ATC code H01BA01). Glucagen is used to raise blood glucose rapidly in emergency situations. It is indicated for severe hypoglycemia and insulin overdose, providing a rapid counter‑regulatory response.

Glucagen Kit is indicated for the acute treatment of conditions that cause dangerously low blood glucose levels.

- Severe hypoglycemia in patients with diabetes when oral glucose is not feasible. - Insulin overdose resulting in prolonged hypoglycemia. - Emergency reversal of hypoglycemia in unconscious or unable‑to‑swallow patients. - Situations requiring rapid restoration of blood glucose during surgical or procedural sedation. - As a rescue medication for children with type 1 diabetes experiencing severe hypoglycemia.

Adverse reactions to glucagon are generally infrequent, but they can be categorized by frequency and severity.

Common: - Nausea or vomiting, typically transient and self‑limited. - Flushing, warmth, or feeling of heat at the injection site. - Headache, mild and usually resolves without treatment. - Pain, redness, or swelling at the injection site. - Dizziness or light‑headedness shortly after injection.

Serious: - Allergic reactions, including rash, urticaria, or anaphylaxis, requiring immediate medical attention. - Marked hypotension or cardiovascular collapse, especially with rapid intravenous administration. - Significant hyperglycemia if an excessive glucagon dose is given, potentially leading to osmotic diuresis.

When using Glucagen Kit, healthcare providers should observe several precautions to ensure safe and effective administration.

- Verify patient identity and confirm indication before injection. - Assess for known hypersensitivity to glucagon or any kit components. - Use appropriate dose and route; avoid rapid intravenous bolus unless specifically indicated. - Monitor blood glucose levels before and after administration to prevent over‑correction. - Caution in patients with pheochromocytoma, adrenal insufficiency, or recent myocardial infarction. - Do not administer intramuscularly in the gluteal region of infants due to risk of nerve injury. - Store the kit according to manufacturer instructions, protecting it from light and extreme temperatures.

Glucagon may interact with other medications; awareness of these interactions helps avoid reduced efficacy or adverse events.

Avoid: - Concurrent use of beta‑blockers, which can blunt the hyperglycemic response to glucagon. - High‑dose insulin therapy that may overwhelm glucagon’s effect, leading to persistent hypoglycemia.

Use with caution: - Catecholamines (e.g., epinephrine) may potentiate cardiovascular effects of glucagon. - Oral hypoglycemic agents, especially sulfonylureas, may increase risk of recurrent hypoglycemia after glucagon administration. - Diuretics that predispose to electrolyte imbalance, potentially affecting glucagon’s action. - Anticholinergic drugs that may reduce gastrointestinal motility, influencing glucose absorption after glucagon.